Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists

Abstract

There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF 1 ) receptor antagonists.

1 . A compound of formula I; 
       
         
           
           
               
               
           
         
         in which R 1  and R 3 , which may be the same or different, are each hydrogen, alkyl C1 to 6 or halo alkyl C1 to 6; 
         R 2  is difluoromethoxyphenyl, in which the phenyl may be optionally substituted by one or more of alkyl C1 to 6, alkoxy C1 to 6, halo, haloalkyl C1 to 6, thioalkyl C1 to 6, —NR 5 R 6 , —CN, haloalkoxy C1 to 6, aryl or -Het or two adjacent carbons are substituted by —O(CH 2 ) x O(CH 2 ) y ; 
         Het is a 5- or 6-membered heteroaryl or a 4, 5- or 6-membered heterocycle; 
         R 4  is alkylene C2 to 10, hydroxy alkyl C1 to 10, each of which may optionally be substituted by aryl, or is —OR 7 , —(CH 2 ) m NR 8 R 9 , —COR 10 , a 5- or 6-membered heteroaryl or a 5- or 6-membered heterocycle, the 5- or 6-membered heteroaryl or 5- or 6-membered heterocycle being optionally substituted by one or more substituents selected from the group alkyl C1 to 10, haloalkyl C1 to 10, hydroxyalkyl C1 to 10, alkoxy(C1 to 3)alkyl(C1 to 3), halo, —CO 2 R 19 , —CONR 20 R 21 , aryl or a 5- or 6-membered heterocycle or heteroaryl; 
         R 5  and R 6 , which may be the same or different, are each hydrogen or alkyl C1 to 6 or R 5  and 
         R 6 , together with the nitrogen to which they are attached, form an optionally substituted saturated or unsaturated cyclic group; 
         R 7  is alkyl C1 to 10, cycloalkyl C3 to 10, optionally fused to an aryl, alkyl(C1 to 6)-cycloalkyl(C3 to 6)-, hydroxy alkyl C1 to 10, hydroxyalkyl(C1 to 6)-(haloalkyl C1 to 6), alkyl(C1 to 6)-oxy-alkyl(C1 to 6), —(CH 2 ) q COOR 22  or a 5- or 6-membered heterocycle; each of which is optionally substituted by one or more of alkyl C1 to 10, alkoxy C1 to 10, hydroxyalkyl C1 to 10, aryl or a 5- or 6-membered heteroaryl, the aryl or a 5- or 6-membered heteroaryl being optionally substituted by alkyl C1 to 10; 
         R 8  and R 9 , which may be the same or different, are each hydrogen, alkyl C1 to 10, halo alkyl C1 to 10, alkyl(C1 to 6)-oxy-alkyl(C1 to 6), —COOR 11 , —COR 12  or arylalkyl C1 to 6 or together with the nitrogen to which they are attached R 8  and R 9  form a 5- or 6-membered heterocycle, optionally substituted by one or more of alkyl C1 to 6; 
         m is an integer 0 or 1; 
         q is an integer from 1 to 6; 
         x and y, which may be the same or different, are each an integer from 1 to 6; 
         R 10  is hydrogen, alkyl C1 to 6, —NR 13 R 14 , hydroxy or alkoxy C1 to 6; 
         R 12  is alkyl C1 to 10, aryl or is a 5- or 6-membered unsaturated heterocyclic ring; 
         R 13  and R 14 , which may be the same or different, are each alkyl C1 to 10, cycloalkyl C3 to 10, cycloalkyl(C3 to 6)alkyl(C1 to 6)-, alkoxy C1 to 10, haloalkyl C1 to 10, aryl, a 5- or 6-membered heterocycle or heteroaryl comprising 1, 2 or 3 heteroatoms; each of which may be optionally substituted by aryl or heteroaryl, or R 13  and R 14  together with the nitrogen to which they are attached form a 5- or 6-membered heterocycle comprising 1, 2 or 3 heteroatoms, which may optionally be fused to a phenyl group, said heterocycle and optionally fused phenyl group being optionally substituted by one or more of alkoxy C1 to 10; 
         R 22  is hydrogen or alkyl C1 to 6; 
         R 11  is alkyl C1 to 6 or aryl; 
         R 19  is hydrogen or alkyl C1 to 10; and 
         R 20  and R 21 , which may be the same or different, are each alkyl C1 to 10; 
         in free form or as a pharmaceutically acceptable salt. 
       
     
     
         2 . A compound according to  claim 1  wherein the compound is of formula II; 
       
         
           
           
               
               
           
         
         in which R 1 , R 3  and R 4  are each as defined in  claim 1 ; and 
         R II  is alkyl C1 to 6, alkoxy C1 to 6, halo, haloalkyl C1 to 6, thioalkyl C1 to 6, —NR 5 R 6 , —CN, haloalkoxy C1 to 6, aryl or -Het or two adjacent carbons are substituted by —O(CH 2 ) x O(CH 2 ) y —; 
         Het is a 5- or 6-membered heteroaryl or a 4, 5- or 6-membered heterocycle; and 
         R 5 , R 6 , x and y are each as defined in  claim 1 ; 
         in free form or as a pharmaceutically acceptable salt. 
       
     
     
         3 . A compound according to  claim 1  wherein the compound is of formula III; 
       
         
           
           
               
               
           
         
         in which R 2 , R 3  and R 4  are each as defined in  claim 1 ; 
         in free form or as a pharmaceutically acceptable salt. 
       
     
     
         4 . A compound according to  claim 1  wherein the compound is of formula IV; 
       
         
           
           
               
               
           
         
         in which R 1 , R 2  and R 4  are each as defined in  claim 1 ; 
         in free form or as a pharmaceutically acceptable salt. 
       
     
     
         5 . A compound according to  claim 1  wherein the compound is of formula V; 
       
         
           
           
               
               
           
         
         in which R 2  and R 4  are each as defined in  claim 1 ; 
         in free form or as a pharmaceutically acceptable salt. 
       
     
     
         6 . A compound according to  claim 1  wherein the compound is of formula I; 
       
         
           
           
               
               
           
         
         in which R 4  is a 5- or 6-membered heteroaryl being optionally substituted by one or more substituents selected from the group alkyl C1 to 10, haloalkyl C1 to 10, hydroxyalkyl C1 to 10, alkoxy(C1 to 3)alkyl(C1 to 3), —CO 2 R 19 , —CONR 20 R 21 , or a 5- or 6-membered heterocycle or heteroaryl; and 
         R 1 , R 2 , R 3 , R 19 , R 20  and R 21  are each as defined in  claim 1 ; 
         in free form or as a pharmaceutically acceptable salt. 
       
     
     
         7 . A compound according to  claim 6  wherein the compound is of Formula VI; 
       
         
           
           
               
               
           
         
         in which R 1 , R 2  and R 3  are each as defined in  claim 6 ; and 
         R VIa  and R VIb , which may be the same or different, are each hydrogen or alkyl C1 to 6; 
         and isomers thereof; 
         in free form or as a pharmaceutically acceptable salt. 
       
     
     
         8 . A compound according to  claim 1  which is 3-(4-(difluoromethoxy)-2-methylphenyl)-7-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2,6-dimethylpyrazolo[5,1-b]oxazole;
 in free form or as a pharmaceutically acceptable salt. 
 
     
     
         9 - 12 . (canceled) 
     
     
         13 . A method of treatment or alleviation of any state with increased endogenous level of CRF or in which the HPA (hypothalamic pituitary axis) is disregulated, or of various diseases induced or facilitated by CRF, which comprises administering to a mammal a therapeutically effective amount of a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof. 
     
     
         14 . A pharmaceutical composition comprising a compound according to  claim 1  in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable adjuvant, diluent or carrier. 
     
     
         15 . A pharmaceutical composition comprising a compound of formula I according to  claim 1  in free form or in pharmaceutically acceptable salt form, in combination with another therapeutically active ingredient, optionally in association, with a pharmaceutically acceptable adjuvant, diluent or carrier.